Influenza Vaccine Production in Brazil

Partnership objectives

Manufactur influenza vaccine to meet the production need of seasonal and pandemic vaccine in Brazil. 

Although it is often confused with other influenza-like illnesses, especially the common cold, influenza is a more severe disease. Although it is often confused with other influenza-like illnesses, especially the common cold, influenza is a more severe disease. Copyright Sanofi Pasteur

What are the health needs and challenges?

Influenza occurs annually, causing significant amount of disease and death, particularly in the elderly, young children and those with certain chronic conditions.

The most common symptoms of the disease are chills, fever, sore throat, muscle pains, severe headache, coughing, weakness/fatigue and general discomfort. Although it is often confused with other influenza-like illnesses, especially the common cold, influenza is a more severe disease than the common cold and is caused by a different type of virus. Influenza can cause mild to severe illness, and at times can lead to death.

Influenza vaccines have been providing good levels of protection for more than 50 years. However, influenza vaccine production is highly complex and involves a large number of steps.

Description of partnership activities and how they address needs and challenges

Sanofi Pasteur has partnered with the Butantan Institute in Brazil since 1999 to deliver seasonal influenza vaccines to the Brazilian Government, with the possibility of switching to pandemic vaccine production if needed. Based on this agreement, Butantan has developed the ability to produce influenza vaccines locally and now provides doses to fulfill most of their public market needs.

Partnership information

Company(ies) Sanofi

Partner(s) Brazilian Ministry of Health, Instituto Butantan

Type of Partner(s) Academia / Hospitals, Government

Therapeutic Focus Vaccine-Preventable Diseases, Women and Children's Health

Disease(s) Children's Health, Influenza

Program Type(s) Availability of Treatment - Technology Transfer - Manufacturing and Entrepreneurial Know-How, Prevention Programs - Vaccines

Targeted Population(s) Children, Elderly

Region(s) Latin America & Caribbean

Number of Countries 1

Country(ies) Brazil

Start Date 2009

More information Sanofi Pasteur

Anticipated completion date Ongoing